Orthofix Medical Reports 4.6% Sales Increase and $22.8 Million Net Loss in Q3 2025

Orthofix Medical Inc. reported a net sales increase of 4.6% for the third quarter of 2025, reaching $205.6 million compared to $196.6 million in the same period last year. The company’s gross profit also rose to $148.5 million, reflecting a gross margin of 72.2%, up from 68.7% in the prior year. However, Orthofix recorded a net loss of $22.8 million for the quarter, a slight improvement from a net loss of $27.4 million in Q3 2024. For the nine months ending September 30, 2025, total net sales were $602.4 million, a 3.2% increase from $583.8 million in the same period of 2024.

The company experienced notable changes in its financial performance, particularly in its Global Orthopedics segment, which saw a 10.1% increase in net sales to $33.6 million, driven by strong growth in the U.S. market. The Global Spine segment also contributed to the overall sales growth, with net sales of $172.1 million, up 3.6% year-over-year. The increase in sales was attributed to higher procedure volumes and the successful adoption of new products, although the discontinuation of the M6 product lines negatively impacted sales by approximately $2.2 million in the third quarter.

Operationally, Orthofix has focused on strategic developments, including the integration of its merger with SeaSpine Holdings Corporation, which has provided cross-selling opportunities. The company reported a positive trend in adjusted EBITDA, which reached $24.6 million for the third quarter, marking a significant margin expansion compared to the previous year. The company’s employee headcount has also increased, reflecting its commitment to enhancing operational capabilities and supporting growth initiatives.

In terms of cash flow, Orthofix reported $5.7 million in net cash provided by operating activities for the nine months ended September 30, 2025, compared to $2.1 million in the same period last year. However, cash and cash equivalents decreased to $62.9 million from $83.2 million at the end of 2024, primarily due to increased capital expenditures and financing activities. The company remains in compliance with its financial covenants under its $275 million credit agreement, which provides a solid foundation for future growth.

Looking ahead, Orthofix anticipates continued growth driven by its strategic focus on expanding its product offerings and enhancing market penetration. The company is optimistic about its ability to leverage synergies from the SeaSpine merger and capitalize on emerging market opportunities. However, it acknowledges potential risks related to ongoing legal matters and market conditions that could impact future performance.